Difference between revisions of "Talk:Programmed death-ligand 1"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922] | *2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922] | ||
==CPS and TPS== | |||
CPS in lymph nodes: | |||
https://pubmed.ncbi.nlm.nih.gov/35420378/ | |||
https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/ | |||
https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ | |||
https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z | |||
==References== | ==References== | ||
{{Reflist|1}} | {{Reflist|1}} | ||
Revision as of 15:19, 29 October 2024
Urothelial carcinoma
Urothelial carcinoma - atezolizumab[1]
Renal cell carcinoma
- 2015 paper: ~ 15% respond to PD-L1[1]
- Biomarkers predict response
- 2018 paper: ~ 70% durable response among those that discontinue d/t side effects[2]
- 2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[3]
- 2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[4]
CPS and TPS
CPS in lymph nodes: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/ https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z
References
- ↑ Rosenberg, JE.; Hoffman-Censits, J.; Powles, T.; van der Heijden, MS.; Balar, AV.; Necchi, A.; Dawson, N.; O'Donnell, PH. et al. (May 2016). "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.". Lancet 387 (10031): 1909-20. doi:10.1016/S0140-6736(16)00561-4. PMID 26952546.